Gradient Investments’s Fulgent Genetics FLGT Stock Holding History

Gradient Investments’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-125	Closed	-$7K	–	1400
2022 Q2	$7K	Buy	+125	New	+$6.87K	﹤0.01%	835

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Gradient Investments's FLGT Position: Q3 2022 in Review

Gradient Investments sold out of Fulgent Genetics (FLGT) in Q3 2022, closing a stake of 125 shares — an estimated $7K sold.

Gradient Investments first reported a position in FLGT in Q2 2022 and held it in 1 quarter. The position peaked at $7K in Q2 2022. 235 funds tracked by Wall St. Rank hold FLGT as of Q3 2022.

Gradient Investments reported no remaining Fulgent Genetics position as of Q3 2022 after selling out during the quarter.
Gradient Investments sold 125 Fulgent Genetics shares in Q3 2022, an estimated $7K.
Gradient Investments first reported a position in Fulgent Genetics in Q2 2022 and held it in 1 quarter.
Gradient Investments's Fulgent Genetics position peaked at $7K in Q2 2022.
235 funds tracked by Wall St. Rank held Fulgent Genetics as of Q3 2022.

Based on Gradient Investments's 13F filing for Q3 2022, filed 14 Oct 2022.